Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…stance to therapy. While bacteria can either promote or inhibit cancer growth, intratumoral bacteria can also be engineered using synt…
…biopsies, infiltrating CD3 + T cells increased after 3 doses of tebentafusp, more so in TCF high patients (3.4 fold change [FC]) compared t…
…esothelin (MSLN) expression and five unbiasedly chosen mucinous CRC tissue blocks were also assessed.Results From 66 co-expressed t…
…SMI and 274 827 comparators. Of 15 neurological conditions, 13 (multiple sclerosis, cerebrovascular disease, dementia, ataxic disorders, epilepsy,…
…aveforms (averaged across the cohort) for emphysema-predominant COPD patients and healthy controlsConclusions This initial dataset h…
…rt a larger study to further investigate higher ICS use in this COPD subgroup.…
…nefits in cardiovascular and renal disease. In murine models of obstructive lung disease, GLP-1 agonists have been shown to reduce airway inflammation a…
… for M. Abscessus. Ten (29%) centres prescribed Bedaquiline for NTM-PD. Treatment duration varied between 3–6 months (n=7,70%) and 6–1…
…ttitudes and access to these therapies are crucial to informing COPD care pathways and the development of personalised care.Aims We …
…Background Pirfenidone and Nintedanib are antifibrotic medications licensed in the UK for Idopathetic…